Ventyx Biosciences Inc (VTYX) - Total Assets
Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) holds total assets worth $211.47 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See VTYX total equity for net asset value and shareholders' equity analysis.
Ventyx Biosciences Inc - Total Assets Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Ventyx Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ventyx Biosciences Inc's total assets of $211.47 Million consist of 83.0% current assets and 17.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $1.00 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ventyx Biosciences Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ventyx Biosciences Inc's current assets represent 83.0% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, down from 88.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Ventyx Biosciences Inc Competitors by Total Assets
Key competitors of Ventyx Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Ventyx Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.86 | 23.52 | 0.17 |
| Quick Ratio | 17.86 | 23.52 | 0.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $189.84 Million | $277.11 Million | $-1.16 Million |
Ventyx Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Ventyx Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.25 |
| Latest Market Cap to Assets Ratio | 3.63 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | $276.56 Million |
| Market Capitalization | $1.00 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ventyx Biosciences Inc's assets at a significant premium (3.63x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Ventyx Biosciences Inc's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual total assets of Ventyx Biosciences Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $276.56 Million | -0.41% |
| 2023-12-31 | $277.69 Million | -25.23% |
| 2022-12-31 | $371.40 Million | +27.42% |
| 2021-12-31 | $291.48 Million | +118872.24% |
| 2020-12-31 | $245.00K | -29.80% |
| 2019-12-31 | $349.00K | -- |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more